Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Agronomics investee Meatable acquires Uncommon Bio platform
(Sharecast News) - Agronomics said on Friday that its portfolio company Meatable has acquired Uncommon Bio's cultured meat technology platform, strengthening its position in the rapidly developing cellular agriculture sector and expanding its capabilities for commercial-scale production. The AIM-traded firm said the deal included Uncommon's key technology, intellectual property, high-performing cell lines and specialist staff, enabling Meatable to integrate its own patented 'opti-ox' system with Uncommon's non-GMO mRNA reprogramming and saRNA differentiation technologies.
Meatable said the combined platform would accelerate time to market, support regulatory approvals across multiple jurisdictions and broaden product development across species including pork, beef, lamb and poultry.
"With this acquisition, Meatable is reinforcing its position as a global leader in cultivated meat, proving what is possible when the world's sharpest minds address one of our greatest challenges - feeding a growing planet amid rising meat demand and shrinking supply," said Jim Mellon, executive chair of Agronomics.
"By combining Uncommon's platform with its own, Meatable will have an enviable offering for prospective customers, offering greater choice and scalability, and answering the global call for a protein supply chain which can help moderate price volatility, and boost food security."
Uncommon chief executive Benjamina Bollag said the company had chosen to focus on therapeutics and wanted "the best home for our technology."
"It's exciting to see Meatable carry our work forward and apply it at scale," he added.
Meatable chief executive Jeff Tripician said the deal "sets a new standard for cultivated meat production," equipping the company to "reliably deliver high-quality cultivated meat at a global scale."
Agronomics had invested £7.9m in Meatable to date, a position carried at £11.7m as at 30 June, representing about 8.1% of the firm's last reported net asset value.
At 1505 BST, shares in Agronomics were down 0.64% at 7.45p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.